• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Advanced Magnetics seeks new Feridex labeling

Article

Contrast media developer Advanced Magnetics announced in late December its submission to the FDA of a supplemental new drug application for Feridex I.V. The application seeks an expansion of indications to include differentiation of liver lesions as

Contrast media developer Advanced Magnetics announced in late December its submission to the FDA of a supplemental new drug application for Feridex I.V. The application seeks an expansion of indications to include differentiation of liver lesions as benign or metastatic. The company also hopes to change the dosing regimen to allow more rapid infusion. Expanding the labeling for Feridex I.V. could make the MRI contrast medium more competitive, according to the company. The agent, which was originally approved by the FDA on Aug. 30, 1996, is being marketed in the U.S. by Berlex Laboratories, a subsidiary of Schering of Germany.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.